SER serina Therapeutics announces completion of enrollment and dosing in cohort 1 of registrational trial of ser-252 for advanced parkinson’
SER serina Therapeutics announces completion of enrollment and dosing in cohort 1 of registrational trial of ser-252 for advanced parkinson’s disease
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.